We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Outcome of Idiopathic Macular Hole

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00941291
Recruitment Status : Completed
First Posted : July 17, 2009
Last Update Posted : July 17, 2009
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to evaluate the role of cataract surgery and cystoid macular edema (CME) on reopening of idiopathic macular holes (IMH).

Condition or disease
Idiopathic Macular Hole

Study Design

Study Type : Observational
Actual Enrollment : 135 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Long-term Outcome of Idiopathic Macular Hole Surgery
Study Start Date : January 2002
Study Completion Date : January 2005
Groups and Cohorts

vitrectomy in pseudophakic eyes
vitrectomy and cataract:combined procedure
vitrectomy followed by cataract extraction
vitrectomy on phakic eyes

Outcome Measures

Primary Outcome Measures :
  1. Long-term outcome of idiopathic macular hole surgery [ Time Frame: 37 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
One hundred and thirty patients (135 eyes) with stage 2, 3, or 4 IMH were included after successful IMH repair

Inclusion Criteria:

  • Patients with with stage 2, 3, or 4 Idiopathic Macular Hole after successful Idiopathic Macular Hole repair

Exclusion Criteria:

  • All patients without stage 2, 3, or 4 Idiopathic Macular Hole repair
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00941291

Ophthalmology Unit CHU Dijon
Dijon, Burgundy, France, 21000
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon
Principal Investigator: Catherine Creuzot-Gracher, MD, PhD Ophthalmology unit CHU Dijon
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Professor Creuzot-Garcher Catherine
ClinicalTrials.gov Identifier: NCT00941291     History of Changes
Other Study ID Numbers: Macular hole 1
First Posted: July 17, 2009    Key Record Dates
Last Update Posted: July 17, 2009
Last Verified: July 2009

Keywords provided by Centre Hospitalier Universitaire Dijon:
idiopathic macular hole

Additional relevant MeSH terms:
Retinal Perforations
Retinal Diseases
Eye Diseases